Clinical Trials Logo

Clinical Trial Details — Status: Terminated

Administrative data

NCT number NCT03451006
Other study ID # 17-003088
Secondary ID
Status Terminated
Phase Phase 2
First received
Last updated
Start date May 24, 2018
Est. completion date December 16, 2021

Study information

Verified date October 2022
Source Mayo Clinic
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This study will test whether chronic metformin administration will improve longevity of the cell, improves its machinery by reducing aging-related biochemical parameters and thereby improving physical performance, as measured by short physical performance battery test.


Description:

Heart disease is the number one cause of death in the United States and disproportionately affects older adults, underscoring the need to examine determinants of survivorship. Recognizing this gap, current guidelines lay emphasis to assess frailty, a key construct prevalent in elderly and known to impact their prognosis.Older persons are commonly frail, manifest hyperglycemia and their health span is truncated by illnesses during which physiological declines together with accumulation of additional deficits results in multimorbidity and functional dependence. High incidence of functional decline and stress hyperglycemia in patients with coronary artery disease (CAD) makes pharmacologic manipulation, an attractive strategy to improve frailty and reduce adverse cardiovascular outcomes. Metformin exerts its effect on health span as a calorie restriction-mimetic through inhibition of mitochondrial complex 1 and activation of activated protein kinase (AMP).This drug is safe and has been shown to prolong life in mammals. Metformin by reducing effects of cellular senescence and improving glycemic control may improve the functioning of older adults. In CAD, cellular senescence and inflammation affect organ dysfunction through interference with tissue homeostasis and regeneration. The deleterious effect of senescence includes pro-inflammatory senescence-associated secretory phenotype (SASP). Normal biological function through alteration in cellular homeostasis and restoration of glycemic control may be achieved by metformin. The phenotypic manifestations of these changes are incompletely characterized as it is yet unknown whether cell-intrinsic regenerative mechanisms can be translated into clinical improvement in physical performance and whether it's chronic administration is safe in older adults. These major gaps in knowledge hinder utilization of metformin as an agent to promote cellular regeneration and to reduce the impact of cellular senescence. Targeting frail individuals with high levels of inflammation and SASP factors would necessitate identification of predictors of improvement with metformin in tissue inflammation and function. A clinomics approach implementing simultaneous assessment of clinical impact coupled with serological profiling would provide enhanced understanding of the local and systemic impact mediated by metformin. Through correlation of molecular profiles with phenotypic expression changes, as proposed herein, investigators will enhance understanding of the regenerative impact of metformin and the basis for clinical improvement in the setting of senescence.


Recruitment information / eligibility

Status Terminated
Enrollment 7
Est. completion date December 16, 2021
Est. primary completion date December 16, 2021
Accepts healthy volunteers No
Gender All
Age group 60 Years and older
Eligibility Inclusion Criteria: - Age = 60 years - Stable CAD - Prediabetes (one of the following criteria should be met) - Fasting plasma glucose: 100-126 mg/dL - HbA1C: 5.7-6.4 - Frailty (Short Physical Performance Battery: Score <9) - Able to return for follow-up - Written informed consent Exclusion criteria: - Pre-existing or new-onset diabetes - Any active malignancy, hematological disorder, post organ transplant, immunocompromised - Cancer requiring treatment in the past 3 years (other than non-melanoma skin cancer) - Dementia [mini mental state examination (MMSE <20)] - Disability (need for assistance in >2 of any six activities on Katz activities of daily living (ADL)46 - Prior stroke with disability - Acute coronary syndrome <3months or participating in cardiac rehabilitation - Severe Parkinson's - Hepatic insufficiency and/or chronic liver disease (cirrhosis) - Chronic kidney disease (GFR < 45 mL/min) - Taking metformin for any indication - Acute alcohol intoxication - Known hypersensitivity to metformin hydrochloride - Acute/chronic metabolic acidosis, including diabetic ketoacidosis, with or without coma

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Metformin
Oral metformin (up to 2gm) will be given in divided doses
Placebo
Oral Placebo will be given in divided doses

Locations

Country Name City State
United States Mayo Clinic in Rochester Rochester Minnesota

Sponsors (1)

Lead Sponsor Collaborator
Mayo Clinic

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Change in Frailty Frailty will be measured by the Short Physical Performance Battery (SPPB). The short physical performance battery (SPPB) is a group of measures that combines the results of the gait speed, chair stand and balance tests. It has been used as a predictive tool for possible disability and can aid in the monitoring of function in older people. The scores range from 0 (worst performance) to 12 (best performance). Frailty is defined as a score of <9. Baseline, 12 months
Primary Change in Balance Score Standing With Feet Close Together This measure is part of the SPPB. The scores range from 0 (not attempted), to 2 (held for 10 seconds). Ability to stand longer in this position indicates greater balance. Baseline, 12 months
Primary Change in Balance Score Standing in Semi Tandem Position This measure is part of the SPPB. The semi tandem position is the heel of one foot place by the big toe of the other foot. The scores range from 0 (not attempted), to 2 (held for 10 seconds). Ability to stand longer in this position indicates greater balance. Baseline, 12 months
Primary Change in Balance Score Standing in Full Tandem Position This measure is part of the SPPB. The full tandem position is with the feet directly in front of each other. The scores range from 0 (not attempted), to 2 (held for 10 seconds). Ability to stand longer in this position indicates greater balance. Baseline, 12 months
Primary Change in Gait Speed This measure is part of the SPPB. Subjects will be asked to walk 8 feet or 2.44 meters at their usual pace. They will be allowed to use a cane or other walking aid if it is their custom. Scores range from 0 = could not do to 4 =<3.1 seconds. Baseline, 12 months
Primary Change in Score, Standing Test From Chair This measure is part of the SPPB. Subjects will be asked to try to stand up from a chair 5 times with arms folded across their chest, and will be timed. Scores range from 0 to 4, with 0 = unable to stand without using arms, and 4 = completing 5 stands in <11.1 seconds. Baseline,12 months
Secondary Change in Interleukin 6 (pg/ml) Serum will be collected to measure the effect of metformin on senescent markers. Baseline, 12 months
Secondary Change in Matrix Metalloproteinase (ng/ml) Serum will be collected to measure the effect of metformin on senescent markers. Baseline, 12 months
Secondary Change in Plasminogen Activator Inhibitor Serum will be collected to measure the effect of metformin on senescent markers. Baseline, 12 months
Secondary Change in Monocyte Chemotactic Protein-1 Serum will be collected to measure the effect of metformin on senescent markers. Baseline, 12 months
Secondary Change in Activin Serum will be collected to measure the effect of metformin on senescent markers. Baseline, 12 months
See also
  Status Clinical Trial Phase
Completed NCT05433233 - Effects of Lifestyle Walking on Blood Pressure in Older Adults With Hypertension N/A
Recruiting NCT06032065 - Sequential Multiple Assessment Randomized Trial of Exercise for PAD: SMART Exercise for PAD (SMART PAD) Phase 3
Completed NCT05293730 - Trial of the Impact of the Electronic Frailty Integrated With Social Needs N/A
Recruiting NCT03932162 - Gene Expression Changes In Young and Geriatric Skin Early Phase 1
Completed NCT04064528 - Effects of Age on Amino Acid Delivery to Tendon N/A
Completed NCT03366129 - Blood-Brain Barrier Disruption in People With White Matter Hyperintensities Who Have Had a Stroke
Completed NCT06029920 - Influence of Overground Walking on Biomarkers, Cognitive Function, and Quality of Life in Elderly With Mild Cognitive Impairment N/A
Recruiting NCT05543980 - Leg Heat Therapy in Elderly Individuals Phase 2
Recruiting NCT05566938 - Study to Design a Precision Nutrition Strategy at a Group Level in the Elderly N/A
Completed NCT04894929 - Comprehensive Geriatric Assessment in the Monitoring of Functional Improvement N/A
Not yet recruiting NCT06071130 - Emotion, Aging, and Decision Making N/A
Enrolling by invitation NCT04641663 - Multi-target Dietary Supplement Tolerability in an Aging Population (MTDSST) N/A
Completed NCT04088006 - The Evaluation of Efficacy and Safety of Hyaluronic Acid Injection on Skin Moisturization and Elasticity N/A
Completed NCT03695081 - Patient Pathway Pharmacist - Optimal Drug-related Care N/A
Recruiting NCT05424263 - Acetate and Age-associated Arterial Dysfunction Phase 2
Completed NCT05601713 - Mitigating Heat-induced Physiological Strain and Discomfort in Older Adults Via Lower Limb Immersion and Neck Cooling N/A
Completed NCT04551339 - Zinc Versus Multivitamin Micronutrient Supplementation in the Setting of COVID-19 N/A
Recruiting NCT04997577 - Speech Perception and High Cognitive Demand N/A
Completed NCT05922475 - Efficacy of Pre-sleep or Post-exercise Protein During 12 Weeks of Resistance Exercise Training N/A
Completed NCT04015479 - Peanut Protein Supplementation to Augment Muscle Growth and Improve Markers of Muscle Quality and Health in Older Adults N/A

External Links